Magnetic resonance imaging in Alzheimer's disease: From diagnosis to monitoring treatment effect

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1198-1209

  Filippi, M ^a   Agosta, F ^a   Frisoni, G B ^b   de Stefano, N ^c   Bizzi, A ^d   Bozzali, M ^e   Falini, A ^a   Rocca, M A ^a   Sorbi, S ^f   Caltagirone, C ^e   Tedeschi, G ^g,h  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^f Azienda Ospedaliero Universitaria di Careggi ^*  (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Institute Hermitage Capodimonte   (Italy)

Author keywords

Alzheimer's disease; Diffusion tensor MRI (DT MRI); Functional MRI (fMRI); Magnetic resonance imaging (MRI); Medial temporal lobe (MTL) atrophy; Proton magnetic resonance spectroscopy (1H MRS); Resting state fMRI; Voxel based morphometry

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CHOLINE; CHOLINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CREATINE; DONEPEZIL; FLUORODEOXYGLUCOSE; HOMOTAURINE; MEMANTINE; N ACETYLASPARTIC ACID; PITTSBURGH COMPOUND B; PLACEBO; XANOMELINE;

ALZHEIMER DISEASE; BOLD SIGNAL; BRAIN ATROPHY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ASSESSMENT; CLINICAL DEMENTIA RATING; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIFFUSION TENSOR IMAGING; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENTORHINAL CORTEX; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMMUNIZATION; IN VIVO STUDY; MEDIAL TEMPORAL LOBE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TOPOGRAPHY; VOLUMETRY; VOXEL BASED MORPHOMETRY; WHITE MATTER;

ALZHEIMER DISEASE; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; TEMPORAL LOBE;

EID: 84874911379     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142949     Document Type: Review

References (180)

1. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66: 1837-44 (2006).
2. Jack CR, Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-65 (2009).
3. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66: 1469-75 (2009).
4. Dubois B. Interest of the new criteria for drug trials in AD. J Nutr Health Aging 13: 356-7 (2009).
5. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9: 1118-27 (2010).
6. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9: 560-74 (2010).
7. Jack CR, Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62: 591-600 (2004).
8. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1: 13-21 (2002).
9. Frisoni GB, Fox NC, Jack CR, Jr., Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6: 67-77 (2010).
10. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82: 239-59 (1991).
11. Thompson PM, Hayashi KM, Dutton RA, Chiang MC, Leow AD, Sowell ER, et al. Tracking Alzheimer's disease. Ann NY Acad Sci 1097: 183-214 (2007).
12. Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hanninen T, et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 19: 23-31 (1998).
13. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71: 743-9 (2008).
14. Frisoni GB, Prestia A, Rasser PE, Bonetti M, Thompson PM. In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. J Neurol 256: 916-24 (2009).
15. Serra L, Cercignani M, Lenzi D, Perri R, Fadda L, Caltagirone C, et al. Grey and white matter changes at different stages of Alzheimer's disease. J Alzheimers Dis 19: 147-59 (2010).
16. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358: 201-5 (2001).
17. Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, et al. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex 11: 1-16 (2001).
18. Boxer AL, Rankin KP, Miller BL, Schuff N, Weiner M, Gorno-Tempini ML, et al. Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia. Arch Neurol 60: 949-56 (2003).
19. Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxelbased morphometry in mild Alzheimer's disease. Neuroimage 14: 298-309 (2001).
20. Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, et al. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry. J Neurol Neurosurg Psychiatry 73: 657-64 (2002).
21. Jones BF, Barnes J, Uylings HB, Fox NC, Frost C, Witter MP, et al. Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study. Cereb Cortex 16: 1701-8 (2006).
22. Frisoni GB, Pievani M, Testa C, Sabattoli F, Bresciani L, Bonetti M, et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 130: 720-30 (2007).
23. Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry 76: 112-4 (2005).
24. Ishii K, Kawachi T, Sasaki H, Kono AK, Fukuda T, Kojima Y, et al. Voxel-based morphometric comparison between earlyand lateonset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol 26: 333-40 (2005).
25. Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S, Rabinovici GD, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 73: 1571-8 (2009).
26. Canu E, Frisoni GB, Agosta F, Pievani M, Bonetti M, Filippi M. Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage. Neurobiol Aging (2012) doi:10.1016/j.neurobiolaging.2010.09.021.
27. Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 246: 477-85 (1999).
28. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 47: 430-9 (2000).
29. Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63: 94-100 (2004).
30. Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52: 1397-403 (1999).
31. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68: 828-36 (2007).
32. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6: 347-61 (2009).
33. Galluzzi S, Geroldi C, Ghidoni R, Paghera B, Amicucci G, Bonetti M, et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257: 2004-14 (2010).
34. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73: 294-301 (2009).
35. Shi F, Liu B, Zhou Y, Yu C, Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies. Hippocampus 19: 1055-64 (2009).
36. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 30: 404-10 (2009).
37. Bozzali M, Filippi M, Magnani G, Cercignani M, Franceschi M, Schiatti E, et al. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology 67: 453-60 (2006).
38. Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27: 934-46 (2005).
39. Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 70: 512-20 (2008).
40. Spampinato MV, Rumboldt Z, Hosker RJ, Mintzer JE. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology 258: 843-52 (2011).
41. Davatzikos C, Fan Y, Wu X, Shen D, Resnick SM. Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging. Neurobiol Aging 29: 514-23 (2008).
42. Wilson SM, Ogar JM, Laluz V, Growdon M, Jang J, Glenn S, et al. Automated MRI-based classification of primary progressive aphasia variants. Neuroimage 47: 1558-67 (2009).
43. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-46 (2007).
44. Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 30: 1-7 (2010).
45. de Jager CA, Honey TE, Birks J, Wilcock GK. Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis. Int J Geriatr Psychiatry 25: 988-97 (2010).
46. Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, et al. Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement 5: 307-17 (2009).
47. van de Pol LA, Hensel A, Barkhof F, Gertz HJ, Scheltens P, van der Flier WM. Hippocampal atrophy in Alzheimer disease: age matters. Neurology 66: 236-8 (2006).
48. Hampel H, Broich K. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging 13: 373-5 (2009).
49. McEvoy LK, Edland SD, Holland D, Hagler DJ, Jr., Roddey JC, Fennema-Notestine C, et al. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord 24: 269-77 (2010).
50. Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowitzki S, Blin O, et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 31: 1443-51, 51 e1 (2010).
51. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 130: 708-19 (2007).
52. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 132: 195-203 (2009).
53. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-72 (2005).
54. Sabattoli F, Boccardi M, Galluzzi S, Treves A, Thompson PM, Frisoni GB. Hippocampal shape differences in dementia with Lewy bodies. Neuroimage 41: 699-705 (2008).
55. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51: 1546-54 (1998).
56. Likeman M, Anderson VM, Stevens JM, Waldman AD, Godbolt AK, Frost C, et al. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed youngonset dementias. Arch Neurol 62: 1410-5 (2005).
57. Rabinovici GD, Seeley WW, Kim EJ, Gorno-Tempini ML, Rascovsky K, Pagliaro TA, et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 22: 474-88 (2007).
58. Barnes J, Godbolt AK, Frost C, Boyes RG, Jones BF, Scahill RI, et al. Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiol Aging 28: 20-8 (2007).
59. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 30: 1711-23 (2009).
60. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5: 828-34 (2006).
61. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52: 1687-9 (1999).
62. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63: 204-12 (2008).
63. Schott JM, Crutch SJ, Frost C, Warrington EK, Rossor MN, Fox NC. Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. Neuropsychologia 46: 1732-7 (2008).
64. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 31: 758-64 (2010).
65. Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F, et al. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 248: 590-8 (2008).
66. Cardenas VA, Chao LL, Studholme C, Yaffe K, Miller BL, Madison C, et al. Brain atrophy associated with baseline and longitudinal measures of cognition. Neurobiol Aging 32: 572-80 (2011).
67. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 45: S3-15 (2009).
68. Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol 255: 56774 (2008).
69. Ho AJ, Hua X, Lee S, Leow AD, Yanovsky I, Gutman B, et al. Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Hum Brain Mapp 31: 499-514 (2010).
70. Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, et al. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage 48: 668-81 (2009).
71. Jack CR, Jr., Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60: 253-60 (2003).
72. Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 362: 1121-2 (2003).
73. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 106: 20954-9 (2009).
74. Hua X, Lee S, Hibar DP, Yanovsky I, Leow AD, Toga AW, et al. Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage 51: 63-75 (2010).
75. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 65: 119-24 (2005).
76. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 77: 1219-22 (2006).
77. Jack CR, Jr., Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65: 1227-31 (2005).
78. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160: 2003-11 (2003).
79. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-72 (2005).
80. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 162: 676-82 (2005).
81. Jack CR, Jr., Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 29: 1285-95 (2008).
82. Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 13: 550-7 (2009).
83. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80 Spec No 2: S146-52 (2007).
84. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131 (2007).
85. Klunk WE, Panchalingam K, Moossy J, McClure RJ, Pettegrew JW. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 42: 1578-85 (1992).
86. Jaarsma D, van der Veenma-Duin L, Korf J. N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease postmortem brain tissue. J Neurol Sci 127: 230-3 (1994).
87. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248: 210-20 (2008).
88. Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66: 718-22 (2006).
89. Kantarci K, Jack CR, Jr., Xu YC, Campeau NG, O'Brien PC, Smith GE, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55: 210-7 (2000).
90. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 24: 843-9 (2003).
91. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 8: 934-42 (2002).
92. Falini A, Bozzali M, Magnani G, Pero G, Gambini A, Benedetti B, et al. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 26: 1159-63 (2005).
93. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, Piccirilli M, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12: 2315-7 (2001).
94. Wang Z, Zhao C, Yu L, Zhou W, Li K. Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiol 50: 312-9 (2009).
95. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003: 26-35 (2004).
96. Meyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, Fein G, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 36: 40-7 (1994).
97. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, et al. 1H MR spectroscopy in common dementias. Neurology 63: 1393-8 (2004).
98. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 41: 276-84 (1999).
99. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49: 1513-21 (1997).
100. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58: 928-35 (2002).
101. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195: 65-72 (1995).
102. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187: 433-7 (1993).
103. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 32: 110-5 (1994).
104. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14: 198-207 (2002).
105. Zhu X, Schuff N, Kornak J, Soher B, Yaffe K, Kramer JH, et al. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 20: 77-85 (2006).
106. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, Molla E, Celda B. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol 11: 187-93 (2004).
107. Fernandez A, Garcia-Segura JM, Ortiz T, Montoya J, Maestu F, Gil-Gregorio P, et al. Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: a combination of techniques that may contribute to the diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 20: 169-77 (2005).
108. Jessen F, Traeber F, Freymann N, Maier W, Schild HH, Heun R, et al. A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease. Dement Geriatr Cogn Disord 20: 178-83 (2005).
109. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D, et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198: 537-45 (1996).
110. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 17: 291-9 (1999).
111. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 355: 1696-7 (2000).
112. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 57: 930-2 (2001).
113. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28: 1330-9 (2007).
114. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 64: 282-9 (2005).
115. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, et al. Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol Aging 27: 926-32 (2006).
116. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162: 667-75 (2005).
117. Garrard P, Schott JM, MacManus DG, Hodges JR, Fox NC, Waldman AD. Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia. Cogn Behav Neurol 19: 185-9 (2006).
118. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203: 829-36 (1997).
119. Mihara M, Hattori N, Abe K, Sakoda S, Sawada T. Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. Neuroreport 17: 413-6 (2006).
120. Traber F, Block W, Freymann N, Gur O, Kucinski T, Hammen T, et al. A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. Eur Radiol 16: 1096-103 (2006).
121. Jessen F, Gur O, Block W, Ende G, Frolich L, Hammen T, et al. A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72: 1735-40 (2009).
122. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67: 528-30 (2006).
123. Bartha R, Smith M, Rupsingh R, Rylett J, Wells JL, Borrie MJ. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 32: 786-93 (2008).
124. Modrego PJ, Pina MA, Fayed N, Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 20: 867-77 (2006).
125. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17: 405-12 (2010).
126. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 154: 1459-61 (1997).
127. Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry 10: 81-8 (2002).
128. Pierpaoli C, Barnett A, Pajevic S, Chen R, Penix LR, Virta A, et al. Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage 13: 1174-85 (2001).
129. Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 32: 2322.e5-2322.e18 (2011).
130. Agosta F, Pievani M, Sala S, Geroldi C, Galluzzi S, Frisoni GB, et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 258: 853-63 (2011).
131. Bai F, Watson DR, Yu H, Shi Y, Yuan Y, Zhang Z. Abnormal resting-state functional connectivity of posterior cingulate cortex in amnestic type mild cognitive impairment. Brain Res 1302: 167-74 (2009).
132. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry 72: 742-6 (2002).
133. Catheline G, Periot O, Amirault M, Braun M, Dartigues JF, Auriacombe S, et al. Distinctive alterations of the cingulum bundle during aging and Alzheimer's disease. Neurobiol Aging 31: 1582-92 (2010).
134. Mielke MM, Kozauer NA, Chan KC, George M, Toroney J, Zerrate M, et al. Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neuroimage 46: 47-55 (2009).
135. Muller MJ, Greverus D, Weibrich C, Dellani PR, Scheurich A, Stoeter P, et al. Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol Aging 28: 398-403 (2007).
136. Rose SE, Chen F, Chalk JB, Zelaya FO, Strugnell WE, Benson M, et al. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 69: 528-30 (2000).
137. Xie S, Xiao JX, Wang YH, Wu HK, Gong GL, Jiang XX. Evaluation of bilateral cingulum with tractography in patients with Alzheimer's disease. Neuroreport 16: 1275-8 (2005).
138. Zhang Y, Schuff N, Jahng GH, Bayne W, Mori S, Schad L, et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 68: 13-9 (2007).
139. Chua TC, Wen W, Chen X, Kochan N, Slavin MJ, Trollor JN, et al. Diffusion tensor imaging of the posterior cingulate is a useful biomarker of mild cognitive impairment. Am J Geriatr Psychiatry 17: 602-13 (2009).
140. Fellgiebel A, Dellani PR, Greverus D, Scheurich A, Stoeter P, Muller MJ. Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Res 146: 283-7 (2006).
141. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Weigand SD, O'Brien PC, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 64: 9024 (2005).
142. Scola E, Bozzali M, Agosta F, Magnani G, Franceschi M, Sormani MP, et al. A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. J Neurol Neurosurg Psychiatry 81: 798-805 (2010).
143. Haller S, Nguyen D, Rodriguez C, Emch J, Gold G, Bartsch A, et al. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis 22: 315-27 (2010).
144. Bozzali M, Parker GJ, Serra L, Embleton K, Gili T, Perri R, et al. Anatomical connectivity mapping: a new tool to assess brain disconnection in Alzheimer's disease. Neuroimage 54: 2045-51 (2011).
145. Kantarci K, Avula R, Senjem ML, Samikoglu AR, Zhang B, Weigand SD, et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 74: 1814-21 (2010).
146. Firbank MJ, Blamire AM, Krishnan MS, Teodorczuk A, English P, Gholkar A, et al. Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease. Psychiatry Res 155: 135-45 (2007).
147. Zhang Y, Schuff N, Du AT, Rosen HJ, Kramer JH, Gorno-Tempini ML, et al. White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain 132: 257992 (2009).
148. Teipel SJ, Meindl T, Wagner M, Stieltjes B, Reuter S, Hauenstein KH, et al. Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis 22: 507-22 (2011).
149. Sala S, Agosta F, Pagani E, Copetti M, Comi G, Filippi M. Microstructural changes and atrophy in brain white matter tracts with aging. Neurobiol Aging 33: 488-498 (2012).
150. Bennett IJ, Madden DJ, Vaidya CJ, Howard DV, Howard JH, Jr. Age-related differences in multiple measures of white matter integrity: A diffusion tensor imaging study of healthy aging. Hum Brain Mapp 31: 378-90 (2010).
151. Ogawa S, Menon RS, Tank DW, Kim SG, Merkle H, Ellermann JM, et al. Functional brain mapping by blood oxygenation leveldependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J 64: 803-12 (1993).
152. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65: 404-11 (2005).
153. Golby A, Silverberg G, Race E, Gabrieli S, O'Shea J, Knierim K, et al. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain 128: 773-87 (2005).
154. Hamalainen A, Pihlajamaki M, Tanila H, Hanninen T, Niskanen E, Tervo S, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging 28: 1889-903 (2007).
155. Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 61: 500-6 (2003).
156. Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 44-50 (2003).
157. Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia 42: 980-9 (2004).
158. Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging 27: 1604-12 (2006).
159. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 26: 10222-31 (2006).
160. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 56: 27-35 (2004).
161. Lenzi D, Serra L, Perri R, Pantano P, Lenzi GL, Paulesu E, et al. Single domain amnestic MCI: A multiple cognitive domains fMRI investigation. Neurobiol Aging 32: 1542-1557 (2011).
162. Sauer J, ffytche DH, Ballard C, Brown RG, Howard R. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. Brain 129: 1780-8 (2006).
163. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8: 700-11 (2007).
164. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 101: 4637-42 (2004).
165. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A 104: 18760-5 (2007).
166. Gili T, Cercignani M, Serra L, Perri R, Giove F, Maraviglia B, et al. Regional brain atrophy and functional disconnection across Alzheimer's disease evolution. J Neurol Neurosurg Psychiatry 82: 58-66 (2011).
167. Li SJ, Li Z, Wu G, Zhang MJ, Franczak M, Antuono PG. Alzheimer Disease: evaluation of a functional MR imaging index as a marker. Radiology 225: 253-9 (2002).
168. Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol 4: e1000100 (2008).
169. Fleisher AS, Sherzai A, Taylor C, Langbaum JB, Chen K, Buxton RB. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage 47: 1678-90 (2009).
170. Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage 31: 496-504 (2006).
171. Wang K, Liang M, Wang L, Tian L, Zhang X, Li K, et al. Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study. Hum Brain Mapp 28: 967-78 (2007).
172. Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 133: 1352-67 (2010).
173. Agosta F, Pievani M, Geroldi C, Copetti M, Frisoni G, Filippi M. Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging (2011) In press.
174. Petrella JR, Prince SE, Wang L, Hellegers C, Doraiswamy PM. Prognostic value of posteromedial cortex deactivation in mild cognitive impairment. PLoS ONE 2: e1104 (2007).
175. Zhang HY, Wang SJ, Liu B, Ma ZL, Yang M, Zhang ZJ, et al. Resting brain connectivity: changes during the progress of Alzheimer disease. Radiology 256: 598-606 (2010).
176. Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 73: 665-71 (2002).
177. Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127: 1574-83 (2004).
178. Kircher TT, Erb M, Grodd W, Leube DT. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am J Geriatr Psychiatry 13: 1006-13 (2005).
179. Lorenzi M, Beltramello A, Mercuri NB, Canu E, Zoccatelli G, Pizzini FB, et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs Aging 28: 205-17 (2011).
180. Jack CR, Jr., Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 6: 212-20 (2010).